Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma (ACC) of all Anatomic Sites of Origin and Other Malignant Salivary Gland Tumors.

Cancer Med · 2025 · PMC11959299 · PMID 40166913

Europe PMC DOI

hedged sentence

0.4200

closest p · 8.4× alpha

0.4200

boldest claim

The sentences

a slight trendp = 0.42not close (p > 0.1)

Additionally, although not significant, there was a slight trend for improved OS and PFS among patients with neutrophil‐to‐lymphocyte ratios greater than five (OS p = 0.42, PFS p = 0.25) and above‐median neutrophil counts (OS p = 0.24, PFS p = 0.18).

also in 1,115 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.